Affivant to Present Data on AFVT-2101 at 37th Annual Meeting of SITC
NEW YORK and BASEL, Switzerland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Affivant, a biotechnology company dedicated to developing novel immune-oncology...
News
Werewolf Therapeutics Presents Preclinical Data on mWTX-330, a Surrogate IL-12 INDUKINE™ Molecule, at the Society for Immunotherapy of Cancer Annual Meeting
- mWTX-330 is designed as a systemically delivered, conditionally activated IL-12 therapy and is a member of a novel class...
Intermountain Healthcare and Las Vegas Raiders Honor Cancer Patients and Survivors During Ceremony with Musician Rachel Platten
Intermountain Healthcare honored five cancer survivors at a recent Las Vegas Raiders football game. L to R: Emma Zarate, Audrey...
Vericel to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum and the Stephens Annual Investment Conference
CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine...
BioSyent Schedules Q3 and YTD 2022 Earnings Release for November 16, 2022
MISSISSAUGA, Ontario, Nov. 10, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its...
Walmart Canada and TELUS Health join forces to provide Walmart associates with comprehensive virtual health and wellbeing services
Over 100,000 associates will benefit from the full suite of TELUS Health’s digital employer health solutions, as retailer becomes first...
Ikena Oncology Announces Initial Clinical Data from IK-175 Program in Urothelial Carcinoma
IK-175 combined with nivolumab showed durable antitumor activity with a 20% ORR and 40% DCR in heavily pretreated urothelial carcinoma...
BlueSphere Bio Presents Data Demonstrating the Potential of Lead Product Candidate at 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting
BSB-1001 is the first product candidate from the TCX-101 platformData supports BSB-1001 as a potential treatment to improve outcomes for...
Sensei Biotherapeutics Presents Preclinical Data at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting
- SNS-101, a highly pH-selective antibody to VISTA, demonstrated anti-tumor effects and promising pharmacokinetic properties in preclinical studies - -...
Immuneering Presents Promising Preclinical Data on its Second Program IMM-6-415 at the 37th Annual Meeting of SITC
IMM-6-415 Shows Preclinical Activity as a Single Agent in RAF and RAS Mutant Tumors and Enhances PD1 and CTLA4 Checkpoint...
Tempest Presents Data Showing TPST-1120-Induced Pharmacodynamic Changes Consistent with Clinical Benefit Observed in Patients with Cancer
TPST-1120 Late-breaking Poster Presentation at SITC Annual MeetingSecond Poster Presentation Demonstrates that Dual Blockade of EP2 and EP4 PGE2 Receptors...
Codiak Presents Preclinical Data on exoASO™-STAT6 and exoASO™-C/EBPβ Programs at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
– exoASO-STAT6 demonstrated durable pharmacokinetic/pharmacodynamic profile in preclinical models; biomarkers with clinical translational potential identified, providing a rationale for selecting cancer...
Beyond Cancer™ Presents Promising New In Vivo Data Showing Ultra-High Concentration Nitric Oxide Therapy (UNO) in Combination with Anti-PD-1 During the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
Data showing UNO in combination with anti-PD-1 treatment leads to significantly higher tumor regression rates UNO in combination with anti-PD-1...
Immutep Announces Promising Initial Clinical Data from INSIGHT-003 at SITC 2022
Media Release First activity evaluation of efti as part of triple combination therapy yields promising early results with 72.7% response...
Allogene Therapeutics Unveils Novel Approach to Generate Engineered AlloCAR T™ Cells to Control Immune Rejection at the Annual Meeting of the Society for Immunotherapy of Cancer
Promising Preclinical Data Highlights a Simple One-Step Gene Editing Strategy to Prevent the Rejection of AlloCAR T™ Cells by Host T...
Cue Biopharma Presents New Positive Data from Ongoing Phase 1 Trial of CUE-101 in Combination with KEYTRUDA(R) for Recurrent/Metastatic HPV+ Head and Neck Cancer at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
Overall response rate (ORR) of 40% and a clinical benefit rate (CBR) of 70% observed to date in first line...
Gritstone Announces Updated Overall Survival Results from GRANITE Phase 1/2 Study and Poster at SITC 2022
-- Median overall survival (OS) for patients with metastatic, microsatellite stable colorectal cancer (MSS-CRC) who had two prior lines of...
Blue Water Vaccines Reports Third Quarter 2022 Financial Results and Recent Business Highlights; Announces 5 Million Share Repurchase Program
Closed private placement in August 2022, with net proceeds of approximately $8.7 millionAnnounced plans to evaluate efficacy of BWV-201 for...
Altamira Therapeutics to Participate at TIDES Europe Oligonucleotide and Peptide Therapeutics Hybrid Event
Hamilton, Bermuda, Nov. 10, 2022 (GLOBE NEWSWIRE) -- • TIDES Europe Event will be held on November 16-18, 2022, in...
RespireRx Pharmaceuticals Inc. Announces that Jeff Margolis, the Company’s CFO is presenting at the Investor Summit Q4
Glen Rock, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in...